165 related articles for article (PubMed ID: 21669937)
21. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.
Blair NF; Brew BJ; Halpern JP
Neurology; 2012 Feb; 78(7):507-8. PubMed ID: 22302545
[No Abstract] [Full Text] [Related]
22. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
23. [Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis].
Tasset I; Aguera E; Gascon F; Giraldo AI; Salcedo M; Cruz AH; Sanchez F; Tunez I
Rev Neurol; 2012 Apr; 54(8):449-52. PubMed ID: 22492096
[TBL] [Abstract][Full Text] [Related]
24. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Phillips JT; Giovannoni G; Lublin FD; O'Connor PW; Polman CH; Willoughby E; Aschenbach W; Pace A; Hyde R; Munschauer FE
Mult Scler; 2011 Aug; 17(8):970-9. PubMed ID: 21421809
[TBL] [Abstract][Full Text] [Related]
25. Disease reactivation after switching from natalizumab to daclizumab.
Uphaus T; Oberwittler C; Groppa S; Zipp F; Bittner S
J Neurol; 2017 Dec; 264(12):2491-2494. PubMed ID: 28975400
[TBL] [Abstract][Full Text] [Related]
26. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.
Sørensen PS; Jensen PE; Haghikia A; Lundkvist M; Vedeler C; Sellebjerg F; Koch-Henriksen N; Fogdell-Hahn A; Myhr KM; Hillert J; Gold R
Mult Scler; 2011 Sep; 17(9):1074-8. PubMed ID: 21511692
[TBL] [Abstract][Full Text] [Related]
27. Plasma exchange in severe acute relapses of multiple sclerosis - Results from a Portuguese cohort.
Correia I; Ribeiro JJ; Isidoro L; Batista S; Nunes C; Macário C; Borges C; Tomaz J; Sousa L
Mult Scler Relat Disord; 2018 Jan; 19():148-152. PubMed ID: 29241141
[TBL] [Abstract][Full Text] [Related]
28. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
[TBL] [Abstract][Full Text] [Related]
29. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.
Abboud H; Petrak A; Mealy M; Sasidharan S; Siddique L; Levy M
Mult Scler; 2016 Feb; 22(2):185-92. PubMed ID: 25921047
[TBL] [Abstract][Full Text] [Related]
30. Natalizumab: state of the art and open questions.
Comi G
Neurol Sci; 2011 Jan; 31 Suppl 3():313-5. PubMed ID: 21107875
[No Abstract] [Full Text] [Related]
31. Drug-induced thrombocytopenia secondary to natalizumab treatment.
Cachia D; Izzy S; Berriosmorales I; Ionete C
BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24879724
[TBL] [Abstract][Full Text] [Related]
32. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients.
von Glehn F; Farias AS; de Oliveira AC; Damasceno A; Longhini AL; Oliveira EC; Damasceno BP; Santos LM; Brandão CO
Mult Scler; 2012 Jul; 18(7):1038-41. PubMed ID: 22041091
[TBL] [Abstract][Full Text] [Related]
33. [Hematological side effects of natalizumab: Correlation with clinical outcome].
Bresch S; Cohen M; Rocher F; Laffon M; Thomas P; Lebrun C
Rev Neurol (Paris); 2012 Feb; 168(2):116-20. PubMed ID: 22100322
[TBL] [Abstract][Full Text] [Related]
34. Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses.
Chapman C; Tubridy N; Cook MJ; Mitchell PJ; MacGregor LR; Lovelock C; Litewka L; Sedal L; Kilpatrick TJ; Butzkueven H
J Clin Neurosci; 2006 Jul; 13(6):636-8. PubMed ID: 16790352
[TBL] [Abstract][Full Text] [Related]
35. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
Perumal JS; Caon C; Hreha S; Zabad R; Tselis A; Lisak R; Khan O
Eur J Neurol; 2008 Jul; 15(7):677-80. PubMed ID: 18459972
[TBL] [Abstract][Full Text] [Related]
36. Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz G; Harrer A; Oppermann K; Wipfler P; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
Mult Scler; 2012 Apr; 18(4):506-9. PubMed ID: 21965415
[TBL] [Abstract][Full Text] [Related]
37. Hypereosinophilia in patients with multiple sclerosis treated with natalizumab.
Abbas M; Lalive PH; Chofflon M; Simon HU; Chizzolini C; Ribi C
Neurology; 2011 Oct; 77(16):1561-4. PubMed ID: 21975205
[TBL] [Abstract][Full Text] [Related]
38. Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.
De Andres C; García MI; Goicoechea H; Martínez-Ginés ML; García-Domínguez JM; Martín ML; Romero-Delgado F; Benguría A; Sanjurjo M; López-Fernández LA
Pharmacogenomics J; 2018 Jan; 18(1):98-105. PubMed ID: 27670768
[TBL] [Abstract][Full Text] [Related]
39. Observations during an elective interruption of natalizumab treatment: a post-marketing study.
Borriello G; Prosperini L; Marinelli F; Fubelli F; Pozzilli C
Mult Scler; 2011 Mar; 17(3):372-5. PubMed ID: 21148264
[TBL] [Abstract][Full Text] [Related]
40. Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness.
Ehler J; Blechinger S; Rommer PS; Koball S; Mitzner S; Hartung HP; Leutmezer F; Sauer M; Zettl UK
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
